Compare DexCom, Inc. (DXCM) vs Futu Holdings Ltd (FUTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Futu Holdings Ltd — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Futu Holdings Ltd trades at $113.71 (market cap $15.25B). The key difference: DexCom, Inc. is far larger — about 2.1× Futu Holdings Ltd's market cap, and Futu Holdings Ltd pays a 2.39% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Futu Holdings Ltd for 34 Days on average.
| DXCM | FUTU | |
|---|---|---|
Market Cap | $31.86B | $15.25B |
Volume | 3,607,070 | 812,567 |
Sector | Health | Financials |
52-Week High | $92.34 | $199.04 |
52-Week Low | $54.84 | $89.76 |
Typical Hold Time | 62 Days | 34 Days |
Enterprise Value | $31.32B | $15.59B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
FUTU trades at $108.76, down 0.84% today amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 10.86, net income margin of 42.92%, and robust revenue growth from $13.6B in 2024 to $22.85B in 2025. Recent Q2 2026 earnings beat expectations, but a securities class action lawsuit deadline on August 25, 2026, adds near-term uncertainty. Analyst consensus is bullish with a 58.34% buy rating and a projected 33.7% upside.
The outlook is mixed: strong earnings growth and low valuation support upside potential, but technical weakness and legal overhangs pose risks. Investors should weigh the company's solid profitability against market sentiment and litigation concerns before positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →
